The closing price of Lemonade Inc (NYSE: LMND) was $16.05 for the day, down -1.83% from the previous closing price of $16.35. On the day, 935787 shares were traded.
Ratios:
Our analysis of LMND’s different ratios will help us gain a deeper understanding of the company. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, TD Cowen on January 10, 2024, initiated with a Market Perform rating and assigned the stock a target price of $17.
On June 20, 2023, Morgan Stanley started tracking the stock assigning a Underweight rating and target price of $14.Morgan Stanley initiated its Underweight rating on June 20, 2023, with a $14 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 11 ’24 when Prosor Maya sold 290 shares for $17.72 per share. The transaction valued at 5,139 led to the insider holds 9,522 shares of the business.
BIXBY TIMOTHY E bought 10,000 shares of LMND for $165,400 on Mar 06 ’24. The Chief Financial Officer now owns 10,000 shares after completing the transaction at $16.54 per share. On Mar 05 ’24, another insider, BIXBY TIMOTHY E, who serves as the Chief Financial Officer of the company, sold 2,161 shares for $16.52 each. As a result, the insider received 35,700 and left with 275,679 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.13 while its Price-to-Book (P/B) ratio in mrq is 1.59.
Stock Price History:
Over the past 52 weeks, LMND has reached a high of $24.81, while it has fallen to a 52-week low of $10.27.
Shares Statistics:
A total of 70.16M shares are outstanding, with a floating share count of 50.49M. Insiders hold about 28.11% of the company’s shares, while institutions hold 39.28% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by Lemonade, Inc. analysts. The consensus estimate for the next quarter is $79.92, with high estimates of $7.28 and low estimates of $12.42.
Analysts are recommending an EPS of between $Consumer Cyclical and $Real Estate for the fiscal current year, implying an average EPS of $Healthcare.
